TN2013000501A1 - Neutralizing prolactin receptor antibody mat3 and its therapeutic use - Google Patents

Neutralizing prolactin receptor antibody mat3 and its therapeutic use

Info

Publication number: TN2013000501A1
Authority: TN; Tunisia
Prior art keywords: prolactin receptor; benign; receptor antibody; prevention; treatment
Prior art date: 2011-06-03

Application number

TNP2013000501A

Other languages

English (en)

Inventor

Christoph Freiberg

Christiane Otto

Lars Linden

Axel Harrenga

Mark Trautwein

Simone Greven

Andreas Wilmen

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-03

Filing date

2013-12-02

Publication date

2015-03-30

2013-12-02 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2015-03-30 Publication of TN2013000501A1 publication Critical patent/TN2013000501A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Microbiology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Cell Biology (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

TNP2013000501A 2011-06-03 2013-12-02 Neutralizing prolactin receptor antibody mat3 and its therapeutic use TN2013000501A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11168644A EP2530089A1 (fr)	2011-06-03	2011-06-03	Anticorps neutralisant Mat3 contre le récepteur de prolactine et son utilisation thérapeutique
PCT/EP2012/060078 WO2012163932A1 (fr)	2011-06-03	2012-05-31	Anticorps neutralisant le récepteur de la prolactine mat3 et usage thérapeutique associé

Publications (1)

Publication Number	Publication Date
TN2013000501A1 true TN2013000501A1 (en)	2015-03-30

Family

ID=46331236

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000501A TN2013000501A1 (en)	2011-06-03	2013-12-02	Neutralizing prolactin receptor antibody mat3 and its therapeutic use

Country Status (37)

Country	Link
US (2)	US9353186B2 (fr)
EP (2)	EP2530089A1 (fr)
JP (1)	JP5859641B2 (fr)
KR (1)	KR101920521B1 (fr)
CN (1)	CN103764679B (fr)
AP (1)	AP2013007266A0 (fr)
AR (1)	AR086631A1 (fr)
AU (1)	AU2012264765B2 (fr)
BR (1)	BR112013030995B1 (fr)
CA (1)	CA2837736C (fr)
CL (1)	CL2013003459A1 (fr)
CO (1)	CO6852025A2 (fr)
CR (1)	CR20130632A (fr)
CU (1)	CU20130163A7 (fr)
CY (1)	CY1117660T1 (fr)
DK (1)	DK2714740T3 (fr)
DO (1)	DOP2013000285A (fr)
EA (1)	EA029316B1 (fr)
EC (1)	ECSP13013063A (fr)
ES (1)	ES2572215T3 (fr)
HR (1)	HRP20160506T1 (fr)
HU (1)	HUE028775T2 (fr)
IL (1)	IL229504B (fr)
MA (1)	MA35237B1 (fr)
ME (1)	ME02659B (fr)
MX (1)	MX343683B (fr)
PE (1)	PE20141158A1 (fr)
PH (1)	PH12013502494A1 (fr)
PL (1)	PL2714740T3 (fr)
RS (1)	RS54727B1 (fr)
SG (1)	SG195060A1 (fr)
SI (1)	SI2714740T1 (fr)
TN (1)	TN2013000501A1 (fr)
TW (1)	TWI548649B (fr)
UY (1)	UY34116A (fr)
WO (1)	WO2012163932A1 (fr)
ZA (1)	ZA201309683B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112014022692A8 (pt)	2012-03-14	2021-07-20	Regeneron Pharma	molécula de ligação de antígeno multiespecífica
TW201920283A (zh) *	2012-12-24	2019-06-01	美商艾伯維有限公司	催乳激素受體結合蛋白質及其用途
US9545451B2 (en)	2013-08-21	2017-01-17	Regeneron Pharmaceuticals, Inc.	Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh)	2013-08-21	2018-11-21	再生元醫藥公司	抗－ｐｒｌｒ抗體及其用途
AU2016289480C1 (en)	2015-07-06	2021-10-21	Regeneron Pharmaceuticals, Inc.	Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (fr)	2016-04-28	2019-03-06	Regeneron Pharmaceuticals, Inc.	Procédés de production de molécules multispécifiques se liant à l'antigène
JP7174699B2 (ja)	2016-11-29	2022-11-17	レゲネロンファーマシューティカルス，インコーポレーテッド	Ｐｒｌｒ陽性乳癌の治療方法
TW201836647A (zh)	2017-04-06	2018-10-16	美商艾伯維有限公司	抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
KR20200027494A (ko)	2017-07-10	2020-03-12	바이엘 파마 악티엔게젤샤프트	남성 및 여성 패턴 탈모를 위한 프로락틴 수용체 항체
EP3587445B1 (fr) *	2017-08-10	2023-12-13	Grifols Diagnostic Solutions Inc.	Marqueur d'oligomérisation comprenant une région fc d'une immunoglobulin et un domaine polyhis
AU2019218892B2 (en)	2018-02-07	2025-08-14	Regeneron Pharmaceuticals, Inc.	Methods and compositions for therapeutic protein delivery
UY39610A (es)	2021-01-20	2022-08-31	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
EP4428150A1 (fr)	2023-03-07	2024-09-11	Peptide Logic LLC	Anticorps ou fragment de liaison à l'antigène de celui-ci
CN116655791B (zh) *	2023-05-06	2023-11-07	浙江触奇生物科技有限公司	一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用
CN120388750A (zh) *	2025-04-15	2025-07-29	绵阳市妇幼保健院(绵阳市儿童医院)	一种子宫内膜异位症患者哺乳期复查随访数据处理系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4657760A (en)	1979-03-20	1987-04-14	Ortho Pharmaceutical Corporation	Methods and compositions using monoclonal antibody to human T cells
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
CA2103887C (fr)	1991-12-13	2005-08-30	Gary M. Studnicka	Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
JP4436457B2 (ja)	1995-08-18	2010-03-24	モルフォシスアイピーゲーエムベーハー	蛋白質／（ポリ）ペプチドライブラリー
GB9701425D0 (en)	1997-01-24	1997-03-12	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
WO2003008583A2 (fr)	2001-03-02	2003-01-30	Sagres Discovery	Nouvelles compositions et methodes relatives au cancer
US7705120B2 (en)	2001-06-21	2010-04-27	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1325930A1 (fr) *	2002-01-08	2003-07-09	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Variants de Prolactin de mammifère
US20090220495A1 (en)	2005-04-07	2009-09-03	Abdallah Fanidi	Cancer Related Genes (PRLR)
US7422899B2 (en)	2005-10-05	2008-09-09	Biogen Idec Ma Inc.	Antibodies to the human prolactin receptor
GEP20125612B (en) *	2006-08-18	2012-08-27	Novartis Ag	Prlr-specific antibody and usage thereof
EP2332995A1 (fr) *	2009-12-10	2011-06-15	Bayer Schering Pharma Aktiengesellschaft	Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique

2011
- 2011-06-03 EP EP11168644A patent/EP2530089A1/fr not_active Withdrawn
2012
- 2012-05-31 AP AP2013007266A patent/AP2013007266A0/xx unknown
- 2012-05-31 HU HUE12729030A patent/HUE028775T2/en unknown
- 2012-05-31 DK DK12729030.2T patent/DK2714740T3/da active
- 2012-05-31 WO PCT/EP2012/060078 patent/WO2012163932A1/fr not_active Ceased
- 2012-05-31 SG SG2013085816A patent/SG195060A1/en unknown
- 2012-05-31 AU AU2012264765A patent/AU2012264765B2/en active Active
- 2012-05-31 JP JP2014513160A patent/JP5859641B2/ja active Active
- 2012-05-31 MX MX2013014174A patent/MX343683B/es active IP Right Grant
- 2012-05-31 US US14/123,517 patent/US9353186B2/en active Active
- 2012-05-31 ME MEP-2016-91A patent/ME02659B/fr unknown
- 2012-05-31 EP EP12729030.2A patent/EP2714740B1/fr active Active
- 2012-05-31 ES ES12729030T patent/ES2572215T3/es active Active
- 2012-05-31 RS RS20160322A patent/RS54727B1/sr unknown
- 2012-05-31 PL PL12729030T patent/PL2714740T3/pl unknown
- 2012-05-31 CA CA2837736A patent/CA2837736C/fr active Active
- 2012-05-31 EA EA201301356A patent/EA029316B1/ru not_active IP Right Cessation
- 2012-05-31 PH PH1/2013/502494A patent/PH12013502494A1/en unknown
- 2012-05-31 SI SI201230553A patent/SI2714740T1/sl unknown
- 2012-05-31 KR KR1020137034848A patent/KR101920521B1/ko active Active
- 2012-05-31 CN CN201280038107.4A patent/CN103764679B/zh active Active
- 2012-05-31 BR BR112013030995-4A patent/BR112013030995B1/pt active IP Right Grant
- 2012-05-31 PE PE2013002749A patent/PE20141158A1/es active IP Right Grant
- 2012-05-31 HR HRP20160506TT patent/HRP20160506T1/hr unknown
- 2012-06-01 UY UY0001034116A patent/UY34116A/es not_active Application Discontinuation
- 2012-06-01 AR ARP120101933A patent/AR086631A1/es active IP Right Grant
- 2012-06-01 TW TW101119849A patent/TWI548649B/zh active
2013
- 2013-11-19 IL IL229504A patent/IL229504B/en active IP Right Grant
- 2013-12-02 MA MA36513A patent/MA35237B1/fr unknown
- 2013-12-02 TN TNP2013000501A patent/TN2013000501A1/fr unknown
- 2013-12-03 CR CR20130632A patent/CR20130632A/es unknown
- 2013-12-03 CU CU2013000163A patent/CU20130163A7/es unknown
- 2013-12-03 EC ECSP13013063 patent/ECSP13013063A/es unknown
- 2013-12-03 CO CO13283823A patent/CO6852025A2/es not_active Application Discontinuation
- 2013-12-03 CL CL2013003459A patent/CL2013003459A1/es unknown
- 2013-12-03 DO DO2013000285A patent/DOP2013000285A/es unknown
- 2013-12-20 ZA ZA2013/09683A patent/ZA201309683B/en unknown
2016
- 2016-04-28 US US15/140,629 patent/US9777063B2/en active Active
- 2016-06-17 CY CY20161100549T patent/CY1117660T1/el unknown

Also Published As

Publication number	Publication date
CN103764679B (zh)	2016-05-04
EA201301356A1 (ru)	2014-09-30
EP2714740B1 (fr)	2016-03-30
IL229504A0 (en)	2014-01-30
EP2530089A1 (fr)	2012-12-05
HUE028775T2 (en)	2017-01-30
CR20130632A (es)	2014-02-04
CA2837736C (fr)	2018-11-20
SG195060A1 (en)	2013-12-30
AR086631A1 (es)	2014-01-08
MA35237B1 (fr)	2014-07-03
BR112013030995B1 (pt)	2021-11-09
AU2012264765B2 (en)	2016-07-28
SI2714740T1 (sl)	2016-06-30
UY34116A (es)	2013-01-03
BR112013030995A2 (pt)	2016-11-22
ECSP13013063A (es)	2014-01-31
US20160319029A1 (en)	2016-11-03
DOP2013000285A (es)	2014-03-16
EA029316B1 (ru)	2018-03-30
WO2012163932A1 (fr)	2012-12-06
CA2837736A1 (fr)	2012-12-06
AU2012264765A1 (en)	2013-12-19
JP5859641B2 (ja)	2016-02-10
HRP20160506T1 (hr)	2016-06-17
CL2013003459A1 (es)	2014-08-08
MX343683B (es)	2016-11-17
RS54727B1 (sr)	2016-10-31
US20140141003A1 (en)	2014-05-22
EP2714740A1 (fr)	2014-04-09
HK1195081A1 (zh)	2014-10-31
IL229504B (en)	2018-10-31
TW201302798A (zh)	2013-01-16
PL2714740T3 (pl)	2016-08-31
US9353186B2 (en)	2016-05-31
ZA201309683B (en)	2016-08-31
CO6852025A2 (es)	2014-01-30
PE20141158A1 (es)	2014-09-26
US9777063B2 (en)	2017-10-03
CN103764679A (zh)	2014-04-30
ME02659B (fr)	2017-06-20
JP2014522239A (ja)	2014-09-04
TWI548649B (zh)	2016-09-11
AP2013007266A0 (en)	2013-11-30
ES2572215T3 (es)	2016-05-30
KR101920521B1 (ko)	2018-11-21
DK2714740T3 (da)	2016-05-30
CU20130163A7 (es)	2014-04-24
NZ618316A (en)	2016-01-29
MX2013014174A (es)	2014-11-13
KR20140036275A (ko)	2014-03-25
CY1117660T1 (el)	2017-05-17
PH12013502494A1 (en)	2014-01-20

Publication	Publication Date	Title
TN2013000501A1 (en)	2015-03-30	Neutralizing prolactin receptor antibody mat3 and its therapeutic use
TN2012000294A1 (en)	2013-12-12	Neutralizing prolactin receptor antibodies and their therapeutic use
MX2019000586A (es)	2021-06-15	Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
MX2022008523A (es)	2022-09-26	Compuestos que interactuan con glicanos y metodos de uso.
MX2017011600A (es)	2018-06-13	Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
PH12014501292A1 (en)	2014-09-08	6,7-dihydro-5h-benzo[7]annulene derivatives, methods for the production thereof, pharmaceutical preparations that contain said 6,7-dihydro-5h-benzo[7]annulene derivatives, and use thereof to produce drugs
MX2015016550A (es)	2016-12-12	Antagonistas de imidazolil progesterona.
EA201491344A1 (ru)	2015-04-30	Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона
TW201613615A (en)	2016-04-16	Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy
MX2014013763A (es)	2015-02-20	Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer.
PH12012501812A1 (en)	2012-12-10	Compositions and methods for non-toxic delivery of antiprogestins
WO2010104691A3 (fr)	2011-01-13	Composés ostrogéniques et leurs procédés d'utilisation
EA201491284A1 (ru)	2014-09-30	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ОПУХОЛЕЙ, ЭКСПРЕССИРУЮЩИХ EGFR И N-ГЛИКОЛИЛГАНГЛИОЗИД GM3 (NEUGcGM3)
RU2009123421A (ru)	2010-12-27	Способ применения наноформы транс-резвератрола для лечения и профилактики гормонозависимых пролиферативных процессов, в том числе опухолей